These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34916092)

  • 21. Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.
    Matteucci KC; Correa AAS; Costa DL
    Front Cell Infect Microbiol; 2022; 12():905278. PubMed ID: 35669122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autophagy Induction as a Host-Directed Therapeutic Strategy against
    Adikesavalu H; Gopalaswamy R; Kumar A; Ranganathan UD; Shanmugam S
    Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34070995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic host-directed strategies to improve outcome in tuberculosis.
    Young C; Walzl G; Du Plessis N
    Mucosal Immunol; 2020 Mar; 13(2):190-204. PubMed ID: 31772320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host-directed therapies offer novel opportunities for the fight against tuberculosis.
    Machelart A; Song OR; Hoffmann E; Brodin P
    Drug Discov Today; 2017 Aug; 22(8):1250-1257. PubMed ID: 28533187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis.
    Ayodele S; Kumar P; van Eyk A; Choonara YE
    Biomed Pharmacother; 2023 Jun; 162():114588. PubMed ID: 36989709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.
    du Plessis N; Kotze LA; Leukes V; Walzl G
    Front Cell Infect Microbiol; 2018; 8():332. PubMed ID: 30298121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Host cell environments and antibiotic efficacy in tuberculosis.
    Day NJ; Santucci P; Gutierrez MG
    Trends Microbiol; 2024 Mar; 32(3):270-279. PubMed ID: 37709598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Host-directed therapy against tuberculosis: Concept and recent developments.
    Udinia S; Suar M; Kumar D
    J Biosci; 2023; 48():. PubMed ID: 38088376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycobacterium tuberculosis: Surviving and Indulging in an Unwelcoming Host.
    Mishra A; Surolia A
    IUBMB Life; 2018 Sep; 70(9):917-925. PubMed ID: 30129097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic code during mycobacterial infections: therapeutic implications for tuberculosis.
    Fatima S; Kumari A; Agarwal M; Pahuja I; Yadav V; Dwivedi VP; Bhaskar A
    FEBS J; 2022 Jul; 289(14):4172-4191. PubMed ID: 34453865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies.
    Tiwari D; Martineau AR
    Semin Immunol; 2023 Jan; 65():101672. PubMed ID: 36469987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits.
    Datta M; Via LE; Dartois V; Weiner DM; Zimmerman M; Kaya F; Walker AM; Fleegle JD; Raplee ID; McNinch C; Zarodniuk M; Kamoun WS; Yue C; Kumar AS; Subudhi S; Xu L; Barry CE; Jain RK
    Proc Natl Acad Sci U S A; 2024 Apr; 121(14):e2321336121. PubMed ID: 38530888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis.
    Nathan C; Gold B; Lin G; Stegman M; de Carvalho LP; Vandal O; Venugopal A; Bryk R
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S25-33. PubMed ID: 18762150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future.
    Rao M; Ippolito G; Mfinanga S; Ntoumi F; Yeboah-Manu D; Vilaplana C; Zumla A; Maeurer M
    Int J Infect Dis; 2019 Mar; 80S():S62-S67. PubMed ID: 30685590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity in tuberculosis.
    Cadena AM; Fortune SM; Flynn JL
    Nat Rev Immunol; 2017 Nov; 17(11):691-702. PubMed ID: 28736436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients.
    Restrepo BI
    Tuberculosis (Edinb); 2016 Dec; 101S():S69-S72. PubMed ID: 27720378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages.
    Genestet C; Bernard-Barret F; Hodille E; Ginevra C; Ader F; Goutelle S; Lina G; Dumitrescu O;
    Tuberculosis (Edinb); 2018 Jul; 111():67-70. PubMed ID: 30029917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Host-Directed Therapeutic Strategies for Tuberculosis.
    Kolloli A; Subbian S
    Front Med (Lausanne); 2017; 4():171. PubMed ID: 29094039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Host-directed therapies for malaria and tuberculosis: common infection strategies and repurposed drugs.
    Baindara P; Agrawal S; Franco OL
    Expert Rev Anti Infect Ther; 2022 Jun; 20(6):849-869. PubMed ID: 35188056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.